Janus Henderson Group PLC Iveric Bio, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $119 Million - $180 Million	-4,530,378 Reduced 96.65%	156,831 $6.17 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $2.49 Million - $3.27 Million	133,305 Added 2.93%	4,687,209 $114 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $9.65 Million - $13.4 Million	-559,587 Reduced 10.94%	4,553,904 $97.5 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $28.5 Million - $56.4 Million	-3,036,228 Reduced 37.26%	5,113,491 $91.7 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $61.1 Million - $127 Million	6,704,654 Added 463.97%	8,149,719 $78.4 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $17.4 Million - $24.1 Million	1,433,850 Added 12785.11%	1,445,065 $24.3 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $155,103 - $210,617	11,215 New	11,215 $188,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.